Explore SZBL
地址：深圳市光明区光侨路高科创新中心
电话：+86-755-86967710
邮箱：webmaster@szbl.ac.cn
电话：+86-755-86967710
邮箱：webmaster@szbl.ac.cn
Tengfei Guo, Ph.D./
Institute/Center
Institute of Neurological and Psychiatric Disorders ，Institute of Biomedical Engineering
Email
tengfei.guo(at)szbl.ac.cn
Research Direction
Medicine and Translational Research,Neuroscience,Biomedical Engineering
Homepage Link
Timeline
Areas
Results
Honors
Media
Recruitment
Papers
Timeline
2020 - Present
Shenzhen Bay Laboratory
Junior Principal Investigator
2018.5-2020.11
University of California, Berkeley, USA
Postdoctoral Fellow
2014.11-2018.04
Technical University of Munich
PhD
2013.09-2014.09
Heidelberg University
MSc in Medical Physics
2011.09-2013.08
Shanghai Jiao Tong University
M.E. in Biomedical Engineering
2007.09-2011.06
Sichuan University
Bachelor in Medical information Engineering
Research Areas
1. Aging and Alzheimer’s Disease；
2. Neuroimaging, fluid biomarker, early diagnosis, early intervention；
3. Pathological characteristics and pathogenesis of Alzheimer's disease.
Highlights
Early onset characteristics, pathological features, and evolutionary patterns of Alzheimer's disease (AD) have become one of the mainstream directions for early diagnosis and intervention of AD. Led by Dr. Guo Tengfei, the Greater-Bay-Area Healthy Aging Brain Study (GHABS) aging cohort was established (Clinical Trials Registration Number: NCTO6183658,Alzheimer's Research & Therapy2024). This study aims to address the major scientific challenges and international development frontiers related to AD by combining high-tech methods in neurocognitive assessments, biochemical techniques, and multimodal neuroimaging to reveal the evolutionary patterns, risk factors, and protective indicators of AD pathology in the elderly population of the Guangdong-Hong Kong-Macao Greater Bay Area, providing scientific evidence for early diagnosis and intervention in AD in China.
The main academic achievements include:
1) Using brain neuroimaging and biomarkers to reveal the complex relationships and evolutionary patterns between clinical pathologies of AD such as Aβ (β-amyloid) pathology, tau pathology, neuroinflammation, synaptic damage, brain atrophy, and cortical glucose metabolism deficiency (Biological Psychiatry2021;Annals of Neurology2022, 2023, 2024), providing a scientific basis for developing early diagnosis strategies for AD.
2) Developing new methods for PET molecular imaging to accurately quantify in vivo brain AD pathology, revealing the spatial aggregation characteristics and evolutionary patterns of Aβ plaques (Journal of Nuclear Medicine2017;Alzheimer’s & Dementia2018;European Journal of Nuclear Medicine and Molecular Imaging2024) and tau tangles (Brain Communications2022; Neurology 2023) in AD development, and establishing precise grading and early diagnosis methods for AD imaging pathology (Neurology2020a;Alzheimer’s Research & Therapy2023).
3) Based on PET molecular imaging pathology, further elucidating the evolutionary patterns of fluid biomarkers such as peripheral blood or cerebrospinal fluid Aβ pathology (Neurology2020b, 2024;Translational Psychiatry2022), tau pathology (Alzheimer’s Research & Therapy2020, 2021), neuroinflammation (Molecular Neurodegeneration2024), and neurodegeneration (Alzheimer’s & Dementia2023) during AD development, and establishing an early screening program for AD based on fluid biomarkers. These efforts have important clinical value for understanding the evolutionary patterns of AD pathology and early diagnosis and treatment.
Key finding one: Sequences of Aβ biomarkers in AD.
Key finding two: β-amyloid PET imaging reference regions and SUVR images.
Key finding three: Sequences of different fluid and imaging biomarkers in the AD continuum.
Honors
2018 Alavi-Mandell Publication Award, Society of Nuclear Medicine & Molecular Imaging (SNMMI)
2020 Human amyloid imaging “Young Investigator Travel Scholarship”
2020 American Alzheimer’s Association “Young Investigator” Honorable Mention Award
2023 Alzheimer’s Association International Conferience “Young Investigator Travel Scholarship”
2023 Shenzhen basic research Foundation for Excellent Young Scholars
2023 Guangdong Science Foundation for Distinguished Young Scholars
2024 National Science Fund for Excellent Young Scholars
Media
Recruitment
Papers
1.Pan Sun, Zhengbo He, Anqi Li, Jie Yang, Yalin Zhu, Yue Cai, Ting Ma, Shaohua Ma,Tengfei Guo*.“Spatial and Temporal Patterns of Cortical Mean Diffusivity in Alzheimer’s Disease and Suspected Non-Alzheimer’s Disease Pathophysiology”,Alzheimer’s & Dementia, 2024, DOI: 10.1002/alz.14176. (* Corresponding author)
2.Tengfei Guo*, Anqi Li, Pan Sun, Zhengbo He, Yue Cai, Guoyu Lan, Lin Liu, Jieyin Li, Jie Yang, Yalin Zhu, Ruiyue Zhao, Xuhui Chen, Dai Shi, Zhen Liu, Qingyong Wang, Linsen Xu, Liemin Zhou, Pengcheng Ran, Xinlu Wang, Kun Sun, Jie Lu*, Ying Han*. “Astrocyte reactivity is associated with tau tangle load and cortical thinning in Alzheimer’s disease”,Molecular Neurodegeneration, 2024, 19 (58). (* Corresponding author)
3. Anqi Li, Ruiyue Zhao, Mingkai Zhang, Pan Sun, Yue Cai, Lin Zhu, Hank Kung, Ying Han, Xinlu Wang*,Tengfei Guo*. “[18F]-D3FSP β-amyloid PET imaging in older adults and Alzheimer’s disease”,European Journal of Nuclear Medicine and Molecular Imaging, 2024, DOI: 10.1007/s00259-024-06835-2. (* Corresponding author)
4. Guoyu Lan, Xuhui Chen, Jie Yang, Pan Sun, Yue Cai, Anqi Li, Yalin Zhu, Zhen Liu, Shaohua Ma,Tengfei Guo*. “Microglial reactivity correlates to presynaptic loss independent of β-amyloid and tau”.Annals of Neurology, 2024,95 (5), 917-928. (* Corresponding author)
5. Yue Cai, Dai Shi, Guoyu Lan, Linting Chen, Yanni Jiang, Liemin Zhou,Tengfei Guo*. “Association of β-amyloid, microglial activation, cortical thickness, and metabolism in older adults without dementia”,Neurology,2024, 102(7), e209205. (* Corresponding author)
6. Jing Du#, Anqi Li#, Dai Shi#, Xuhui Chen, Qingyong Wang, Zhen Liu, Kun Sun,Tengfei Guo*. “Association of APOE4, osteoarthritis, β-amyloid, and tau accumulation in primary motor and somatosensory regions in Alzheimer’s Disease”,Neurology, 2023, 101(1): e40-e49. (* Corresponding author)
7. Guoyu Lan, Anqi Li, Zhen Liu, Shaohua Ma,Tengfei Guo*. “Presynaptic membrane protein dysfunction occurs prior to neurodegeneration and predicts faster cognitive decline”,Alzheimer’s & Dementia, 2023, 19 (6): 2408-2419. (* Corresponding author)
8. Guoyu Lan, Yue Cai, Anqi Li, Zhen Liu, Shaohua Ma,Tengfei Guo*. “Association of presynaptic loss with Alzheimer’s disease and cognitive decline”,Annals of Neurology, 2022, 92(6), 1001-1015. (* Corresponding author)
9.Tengfei Guo*, Deniz Korman, Suzanne L. Baker, Susan M. Landau, William J. Jagust, “Longitudinal cognitive and biomarker measurements support a unidirectional pathway in Alzheimer’s Disease pathophysiology”.Biological Psychiatry, 2021, 89:786–794. (* Corresponding author)
10.Tengfei Guo*, Susan M. Landau, William J. Jagust, “Detecting earlier stages of amyloid deposition using PET in cognitively normal elderly adults”.Neurology, 2020, 94 (14): e1512-e1524. (* Corresponding author)
Contact
Address: Gaoke Innovation Center,Guangming District, Shenzhen
Phone: +86-755-86967710
Email: webmaster@szbl.ac.cn
Postal Code: 518132
Copyright © 2025 Shenzhen Bay Laboratory. All Rights Reserved.